Exploring Cellular Reprogramming.
Epigenetic reprogramming is one line of research into aging. Laboratory findings raise questions about cell function, safety and whether benefits can translate to people.
Studying Cellular Reprogramming
This AI-generated overview introduces epigenetic reprogramming. Its simplified explanations should be read alongside the primary sources below; experimental findings do not establish a treatment for human aging.
The Yamanaka Factors
In 2006, Shinya Yamanaka showed that mature mouse cells could be reprogrammed into pluripotent stem cells using four factors. He shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon for work on cellular reprogramming.
Full reprogramming changes cell identity. Researchers are studying partial reprogramming to investigate whether some cell functions can be improved while retaining that identity.
A 2020 mouse study investigated three factors, OSK, in retinal cells. Its findings do not establish that the approach is safe or effective for reversing aging in people.
Explore a Research Switch
Some experimental systems use doxycycline to control gene expression. This animation illustrates a research concept; it does not predict a biological outcome or show how to use a treatment.
ER-100: Early Human Research
The 2020 Nature study reported improved vision in mouse experiments. In January 2026, Life Biosciences announced FDA clearance of an investigational application for a Phase 1 study of ER-100 in optic neuropathies. Permission to study an investigational therapy is not approval to market it or evidence of a human longevity benefit.